

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177

Anton Amadeus Hörmann ¹, Maximilian Klingler ¹, Maliheh Rezaeianpour ^{1,3},
Nikolas Hörmann ², Ronald Gust ², Soraya Shahhosseini ³ and Elisabeth von Guggenberg ^{1,*}

¹ Department of Nuclear Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria;
anton.hoermann@i-med.ac.at (A.A.H.); Maximilian.Klingler@i-med.ac.at (M.K.); m.rezaeianpour@yahoo.com
(M.R.)

² Department of Pharmaceutical Chemistry, University of Innsbruck, 6020 Innsbruck, Austria;
nikolas.hoermann@uibk.ac.at (N.H.); ronald.gust@uibk.ac.at (R.G.)

³ Pharmaceutical Chemistry and Radiopharmacy Department, School of Pharmacy, Shahid Beheshti University
of Medical Sciences, 1991953381 Tehran, Iran; soraya.shahhosseini@gmail.com

* Correspondence: elisabeth.von-guggenberg@i-med.ac.at; Tel.: +43-512-504-80960

Table of Contents

Figures S. 2

Figure S1: Representative UV-chromatogram of the metabolites **M1-M8**

Figure S2: MALDI-TOF-MS of the different synthesized metabolites **M1-M8**

Figure S3: 400 MHz ¹H NMR of D-glutamic acid dimethyl ester

Figure S4: Representative radiochromatogram of [¹⁷⁷Lu]Lu-**1** and [¹⁷⁷Lu]Lu-**M1** co-analyzed in
different ratios of approx. 1:1 (a) 2:1 (b) and 10:1 (c) using the radiodetector equipped with the high
sensitivity loop (250 µL)




Figure S1: Representative UV-chromatogram of the metabolites **M1-M8**




Figure S2: MALDI-TOF MS spectra of the synthesized metabolites M1-M8




Figure S3: 400 MHz ^1H NMR of **D-glutamic acid dimethyl ester**




Figure S4: Representative radiochromatogram of $[^{177}\text{Lu}]\text{Lu-1}$ and $[^{177}\text{Lu}]\text{Lu-M1}$ co-analyzed in different ratios of approx. 1:1 (a) 2:1 (b) and 10:1 (c) using the radiodetector equipped with the high sensitivity loop (250 μL)